Speech Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Speech Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Mermaid diagram (expand to render)
Neurodegenerative diseases affect the neural pathways controlling speech production, voice generation, and safe swallowing. Speech-language pathologists (SLPs) play a critical role in: [@yorkston2023]
Preserving communication for as long as possible
Maximizing functional speech and voice quality
Managing dysphagia to prevent aspiration pneumonia
Supporting cognitive-linguistic function in dementias
Speech and Voice Disorders in Neurodegeneration
Hypokinetic Dysarthria
Most common in Parkinson's disease and related disorders: [@plowman2024]
Characteristics: Monopitch, reduced loudness, breathy voice, short rushes of speech
Neural substrate: Basal ganglia dysfunction affecting motor programming
Progression: Gradual decline, often preceded by voice changes
Spastic Dysarthria
Associated with upper motor neuron involvement: [@miller2022]
Common in: Multiple System Atrophy (MSA), spinocerebellar ataxias
LSVT LOUD Therapy
Lee Silverman Voice Treatment (LSVT) LOUD is the gold-standard voice therapy for Parkinson's disease, with expanding applications to other neurological conditions. [@duffy2024]
Mechanism
Amplitude-based training: Focuses on increasing vocal loudness
Sensory recalibration: Helps patients recognize normal loudness
Neuroplasticity: Induces plastic changes in the vocal motor [cortex](/brain-regions/cortex)
Protocol
Duration: 4 weeks, 4 sessions per week
Daily practice: 15-30 minutes of voice exercises
Homework: Daily exercises using LSVT techniques
Maintenance: Ongoing practice to preserve gains
Evidence
Dysphagia Management
Swallowing difficulties (dysphagia) are common in:
ALS: 80-90% develop dysphagia
Parkinson's disease: Up to 50% experience dysphagia
MSA: Early and severe involvement
PSP: Progressive dysphagia
Assessment
Clinical swallowing evaluation: Bedside assessment of signs
Videofluoroscopic swallow study (VFSS): Gold standard
Fiberoptic endoscopic evaluation of swallowing (FEES): Bedside alternative
Manometry: Pressure measurements
Therapeutic Interventions
Expiratory muscle strength training (EMST): Improves cough strength
[American Speech-Language-Hearing Association (ASHA)](https://www.asha.org/)
[LSVT Global](https://www.lsvtglobal.com/)
[National Institute on Deafness and Other Communication Disorders (NIDCD)](https://www.nidcd.nih.gov/)
[Parkinson's Foundation - Speech and Swallowing](https://www.parkinson.org/)
Background
The study of Speech Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
Ramig LO, et al, LSVT LOUD and speech therapy for Parkinson's disease (2024)
Yorkston KM, et al, AAC for ALS and related disorders (2023)
Plowman EK, et al, Dysphagia in neurodegenerative disease (2024)
Miller N, et al, Speech and language therapy for Parkinson's disease (2022)
Russell JA, et al, LSVT BIG for movement disorders (2023)
Hillel A, et al, State of the art in AAC (2024)
Duffy JR, Motor Speech Disorders (2024)
Weismer G, Speech motor development and disorders (2023)